Home

Sanj K Patel

CIK 1532218 · CHAIRMAN & CEO · last filed 2026-09-03

Sanj K Patel is a CHAIRMAN & CEO who has filed 77 SEC Form 4 insider transactions across 5 companies since 2011. The most recent filing, for KNSA, was dated Sep 3, 2026. Across all open-market trades the lifetime net is −$71.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$7.25M

Companies

5

Total Filings

77

Lifetime Open-Market Net

-$71.47M

Filer Profile

Reported Address
C/O KINIKSA PHARMACEUTICALS INT'L, PLC
105 PICCADILLY, SECOND FLOOR
LONDON W1J 7NJ
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KNSA CHAIRMAN & CEO 92,348 $78.52 $7.25M -$30.28M 44 2026-09-03
Syros Pharmaceuticals, Inc. (SYRS) Delisted Director — $0.00 — $0 3 2017-09-22
BCRX Director — $8.80 — $0 3 2017-05-25
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted President & CEO 0 — — -$41.19M 19 2015-06-23
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 452 $19.00 $8.6K $0 1 2014-07-21

Recent Filings

77 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-03 KNSA Mixed +16,174 -$1.20M EDGAR
2026-09-03 KNSA Mixed +16,174 -$1.20M EDGAR
2026-06-02 KNSA Conv (C) +900,000 $0 EDGAR
2026-05-01 KNSA Mixed — -$1.12M EDGAR
2026-04-28 KNSA Notice (144) −344,591 -$17.78M EDGAR
2026-04-08 KNSA Mixed +5,160 -$525.0K EDGAR
2026-04-06 KNSA Notice (144) −219,591 -$10.98M EDGAR
2026-04-03 KNSA Mixed +11,014 -$496.4K EDGAR
2025-11-14 KNSA Gift (G) — $0 EDGAR
2025-10-22 KNSA Mixed — -$9.04M EDGAR
Showing 1–10 of 77
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.